Tillner, Joachim

A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials

Tillner, J., Posch, M. G., Wagner, F., Teichert, L., Hijazi, Y., Einig, C., Keil, S., Haack, T., Wagner, M., Bossart, M., et al. (2019) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 164

Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models

Allesøe, R. L., Lundgaard, A. T., Hernández Medina, R., Aguayo-Orozco, A., Johansen, J., Nissen, J. N., Brorsson, C., Mazzoni, G., Niu, L., Biel, J. H., et al. (2023) · Nature Biotechnology

Bioinformatics and Genomic NetworksComputational Drug Discovery Methods

Cited by 111

Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes

Eriksson, O., Haack, T., Hijazi, Y., Teichert, L., Tavernier, V., Laitinen, I., Berglund, J. E., Antoni, G., Velikyan, I., Johansson, L., et al. (2020) · Scientific Reports

Diabetes Treatment and ManagementRadiopharmaceutical Chemistry and Applications

Cited by 46

Glucagon‐like peptide ‐1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial

Corbin, K. D., Carnero, E. A., Allerton, T. D., Tillner, J., Bock, C. P., Luyet, P., Göbel, B., Hall, K. D., Parsons, S. A., Ravussin, E., et al. (2023) · Obesity

Regulation of Appetite and ObesityPharmacology and Obesity Treatment

Cited by 32

Prolonged Glucagon Infusion Does Not Affect Energy Expenditure in Individuals with Overweight/Obesity: A Randomized Trial

Whytock, K. L., Carnero, E. A., Vega, R. B., Tillner, J., Bock, C., Chivukula, K., Yi, F., Meyer, C., Smith, S. R., & Sparks, L. M. (2021) · Obesity

Regulation of Appetite and ObesityPancreatic function and diabetes

Cited by 30

A Metabolomic Signature of Glucagon Action in Healthy Individuals With Overweight/Obesity

Vega, R. B., Whytock, K. L., Gassenhuber, J., Goebel, B., Tillner, J., Agueusop, I., Truax, A. D., Yu, G., Carnero, E., Kapoor, N., et al. (2021) · Journal of the Endocrine Society

Pancreatic function and diabetesMetabolomics and Mass Spectrometry Studies

Cited by 24

Tolerability, safety, and pharmacokinetics of the novel cathepsin A inhibitor SAR164653 in healthy subjects

Tillner, J., Lehmann, A., Paehler, T., Lukacs, Z., Ruf, S., Sadowski, T., Pinquier, J., & Ruetten, H. (2016) · Clinical Pharmacology in Drug Development

Heart Failure Treatment and ManagementPharmacogenetics and Drug Metabolism

Cited by 14